🔎 Trials Near Me

Utama › Adenokarsinoma Esofagus › North Carolina

Kajian klinikal Adenokarsinoma Esofagus di North Carolina

12 kajian untuk Adenokarsinoma Esofagus sedang mencari peserta di lokasi di North Carolina.

Bandar di North Carolina

Teks kajian rasmi (Bahasa Inggeris)

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  • Cone Health MedCenter Asheboro, Asheboro
  • Cone Health Cancer Center at Alamance Regional, Burlington
  • Southeastern Medical Oncology Center-Clinton, Clinton
  • dan 6 lagi
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Okt 2026 · NCT06203600

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Southeastern Medical Oncology Center-Clinton, Clinton
  • Southeastern Medical Oncology Center-Goldsboro, Goldsboro
  • dan 5 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05677490

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  • University of North Carolina Medical Center, Chapel Hill
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07221149

Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma

  • Duke University Medical Center, Durham
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07603375

Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

  • University of North Carolina at Chapel Hill, Chapel Hill
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 50 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06687603

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT06732388

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

  • University of North Carolina School of Medicine, Chapel Hill
Mengambil peserta
Umur 18 hingga 89 · Semua jantina · Dikemas kini 11 Sep 2026 · NCT05753748

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  • Research Site, Charlotte
  • Research Site, Wilmington
  • Research Site, Winston-Salem
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT07431281

Obeticholic Acid for Prevention in Barrett's Esophagus

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT04939051

Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

  • University of North Carolina at Chapel Hill, Chapel Hill
Mengambil peserta
Umur 18 hingga 89 · Semua jantina · Dikemas kini 1 Jul 2026 · NCT05530343

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

  • Research Site, Durham
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Jun 2026 · NCT07284186

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

  • Durham VA Medical Center, Durham, NC, Durham
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Nov 2025 · NCT05563766

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.